Dimemebfe, also known as 5-methoxy-N,N-dimethyl-3-(2-aminoethyl)benzofuran (5-MeO-BFE or 5-MeO-DMBF) or as 1-oxa-5-MeO-DMT, is a psychedelic drug of the benzofuran family related to the psychedelic tryptamine 5-MeO-DMT. It is the analogue and bioisostere of 5-MeO-DMT in which the nitrogen atom of the indole ring has been replaced with an oxygen atom, making dimemebfe a benzofuran rather than tryptamine derivative. The drug has been encountered as a novel designer drug.
Dimemebfe acts as an agonist of the serotonin 5-HT<sub>1A</sub> and 5-HT<sub>2</sub> family of serotonin receptors. It is several times less potent as a serotonin receptor agonist than 5-MeO-DMT and with relatively more activity at the serotonin 5-HT<sub>1A</sub> receptor, but still shows strongest actions at the 5-HT<sub>2</sub> family of receptors.
The chemical synthesis of dimemembfe has been described.
Analogues of dimemebfe include the benzofurans 5-MeO-DiBF (1-oxa-5-MeO-DiPT), 3-APB (1-oxa-AMT), and mebfap (5-MeO-3-APB; 1-oxa-5-MeO-AMT), the benzothiophene S-DMT (1-thia-DMT), and the tryptamine 5-MeO-DMT, among others.
Dimemebfe was first described in the scientific literature by David E. Nichols and colleagues in 1992. Subsequently, it emerged as a novel designer drug by 2012.
Dimemebfe is not a controlled substance in Canada as of 2025.
Dimemebfe is not an explicitly controlled substance in the United States. However, it could be considered a controlled substance under the Federal Analogue Act if intended for human consumption.
Dimemebfe is a Schedule I controlled substance in the United States state of Alabama.